Aktie A3DVJM SALARIUS PHARMACEUTICALS, INC.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen Salarius Pharmaceuticals, Inc.

Aktien

A3DVJM

US79400X3052

SLRX

Markt geschlossen - Nasdaq
Andere Börsenplätze
 22:30:01 03.05.2024 		% 5 Tage % 1. Jan.
0,501 USD -5,04 % Intraday Chart für Salarius Pharmaceuticals, Inc. +1,19 % -22,92 %
25.03. Wall Street eröffnet am Montag vor den Daten zum Wohnungsbau und zur Inflation leicht schwächer MT
25.03. Top-Zuwächse an der Börse MT

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Wall Street Set to Open Modestly Lower Monday Ahead of Housing, Inflation Data
Top Premarket Gainers
North American Morning Briefing : Tech in Focus on -2-
Salarius: Q4 Earnings Snapshot
Salarius Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Salarius Provides Update on Strategic Review Process and Plans to Support Ongoing Seclidemstat Clinical Trials by Further Reducing Expenses
Salarius Pharmaceuticals, Inc. Provides Update on Strategic Review Process and Plans to Support Ongoing Seclidemstat Clinical Trials by Further Reducing Expenses
Salarius Pharmaceuticals Issued U.S. Patent for Next-Generation Targeted Protein Degraders
Salarius Pharmaceuticals, Inc. Announces Update on Hematologic Cancer Phase 1/2 Clinical Trial Be Conducted At the University of Texas MD Anderson Cancer Center
Investigator-initiated Phase 1/2 Clinical Trial Using Salarius Pharmaceuticals’ Seclidemstat in Combination with Azacitidine to Treat Hematologic Cancers Resumes Patient Enrollment
Chronic Myelomonocytic Leukaemia Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023 (Updated)
North American Morning Briefing : Stock Futures -2-
Salarius: Q3 Earnings Snapshot
Salarius Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Salarius Completes FDA Type B Meeting for Seclidemstat Ewing Sarcoma Development Program
Salarius Pharmaceuticals, Inc. Completes FDA Type B Meeting for Seclidemstat Ewing Sarcoma Development Program
Salarius: Q2 Earnings Snapshot
Salarius Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Sector Update: Health Care Stocks Decline Thursday
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A3DVJM Aktie
  4. Nachrichten Salarius Pharmaceuticals, Inc.
  5. Andere Sprachen